Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is modifying human activity all over the world with significant health and economic burden. The advent of the SARS-CoV-2 pandemic prompted the scientific community to learn the virus dynam...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 856657
Main Authors Busà, Rosalia, Sorrentino, Maria Concetta, Russelli, Giovanna, Amico, Giandomenico, Miceli, Vitale, Miele, Monica, Di Bella, Mariangela, Timoneri, Francesca, Gallo, Alessia, Zito, Giovanni, Di Carlo, Daniele, Conaldi, Pier Giulio, Bulati, Matteo
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 24.03.2022
Subjects
B cells
BNT162 Vaccine
BNT162b2
booster dose
COVID-19 - prevention & control
COVID-19 Vaccines
Humans
Immunity, Cellular
Immunology
mRNA vaccine
mRNA Vaccines
RNA, Messenger - genetics
SARS-CoV-2
T cells
T-Lymphocytes
Vaccines, Synthetic
SARS-CoV-2
BNT162b2
B cells
T cells
booster dose
mRNA vaccine
Online AccessGet full text

Cover

More Information
Summary:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is modifying human activity all over the world with significant health and economic burden. The advent of the SARS-CoV-2 pandemic prompted the scientific community to learn the virus dynamics concerning transmissibility, epidemiology, and usefulness of vaccines in fighting emerging health hazards. Pieces of evidence suggest that the first and second doses of mRNA vaccines induce a significant antibody response in vaccinated subjects or patients who recovered from SARS-CoV-2 infection, demonstrating the importance of the previously formed memory. The aim of this work has been to investigate the effects of BNT162b2 Pfizer-BioNTech mRNA-based vaccine booster dose in a cohort of 11 uninfected immunocompetent (ICs), evaluating the humoral and cellular responses, with more carefulness on memory B and T cells. Our findings underscore the potential benefit of the third dose of mRNA vaccine on the lifespan of memory B and T cells, suggesting that booster doses could increase protection against SARS-CoV-2 infection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Suryaprakash Sambhara, Centers for Disease Control and Prevention (CDC), United States
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
Reviewed by: Todd Bradley, Children’s Mercy Hospital, United States; Stephanie Longet, University of Oxford, United Kingdom
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.856657